Irinotecan and oxaliplatin-based regimens in metastatic colorectal cancer and optimization of sequence: a regional cancer center study

Date 29 June 2016
Event ESMO World Congress on Gastrointestinal Cancer 2016
Session ESMO World Congress on Gastrointestinal Cancer 2016 - Abstracts book
Presenter P. Kumari
Citation Annals of Oncology (2016) 27 (2): 86-101. 10.1093/annonc/mdw201
Authors P. Kumari1, S. Narayan1, M. Singhal1, S. Saugat2
  • 1Acharya Tulsi Regional Cancer Treatment and Research Center, Bikaner, India, /
  • 2ATRCTRI, Bikaner, India, /

Abstract

To compare the survival benefit of irinotecan and oxaliplatin-based regimens for metastatic colorectal cancer. Irinotecan followed by oxaliplatin-based regimen and reverse sequence, that is oxaliplatin followed by irinotecan.